Strategic Expansion LTS is a US-based subsidiary focusing on advanced drug delivery technologies including transdermal, oral thin film, microneedles, and active transdermal systems, presenting opportunities to collaborate with US-based pharma firms seeking innovative delivery platforms.

Pain-Free Delivery Microneedle technology enabling painless administration of larger molecules could attract partnerships with biologics or high-mmolecule therapies seeking alternative administration routes for improved patient experience and adherence.

Diverse Tech Stack Existing engagement with major telecom and enterprise platforms (Microsoft 365, T-Systems, managed DNS, email marketing) indicates familiarity with scalable enterprise collaborations and potential for joint digital health or patient engagement initiatives.

Revenue Base Current revenue range situates LTS as a mid-market opportunity with room to scale; targeted outreach to mid-to-large pharmaceutical players and contract manufacturers could unlock larger orders tied to new delivery platforms.

Competitive Positioning As a specialized provider with multiple delivery modalities, LTS can differentiate by offering integrated solutions across transdermal, oral film, and microneedle platforms, appealing to companies seeking end-to-end alternatives to injections.